Ending The AIDS Epidemic as part of the Sustainable Development Goals

Dolutegravir (DTG)/TLD Rolled Out in Nepal

With the dissemination of new HIV testing and treatment guidelines, DTG based regimen (TLD: tenofovir, lamivudine, Dolutegravir) is the preferred first line regimen in Nepal.

NCASC develop and disseminated 2020 HIV Testing and Treatment Guidelines in May 2020. This new National HIV testing and treatment guidelines, 2020 refines the testing strategy for the infants, adults and pregnant, introduces Dolutegravir (DTG) as the first line drugs for all and advocates on rapid initiation of ART. The guidelines also stress on community-based care of PLHIV with differentiated care approach which means less hospital visits for healthy PLHIV and more time to provide for critical patients. Adoption of these new technical and strategic changes will be key to achieve the target for HIV.
[ Download Guideline ]